SHORT COMMUNICATION

Unraveling the drug distribution in brain enabled by MALDI MS imaging with laser-assisted chemical transfer

Shuai Guo, Kening Li, Yanwen Chen, Bin Li*

State Key Laboratory of Natural Medicines and School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 210009, China

Received 22 August 2021; received in revised form 24 October 2021; accepted 3 November 2021

Abstract Accurate localization of central nervous system (CNS) drug distribution in the brain is quite challenging to matrix-assisted laser desorption/ionization (MALDI) mass spectrometry imaging (MSI), owing to the ionization competition/suppression of highly abundant endogenous biomolecules and MALDI matrix. Herein, we developed a highly efficient sample preparation technique, laser-assisted chemical transfer (LACT), to enhance the detection sensitivity of CNS drugs in brain tissues. A focused diode laser source transilluminated the tissue slide coated with α-cyano-4-hydroxycinnamic acid, an optimal matrix to highly absorb the laser radiation at 405 nm, and a very thin-layer chemical film mainly containing drug molecule was transferred to the acceptor glass slide. Subsequently, MALDI MSI was performed on the chemical film without additional sample treatment. One major advantage of LACT is to minimize ionization competition/suppression from the tissue itself by removing abundant endogenous lipid and protein components. The superior performance of LACT led to the successful visualization of regional distribution patterns of 16 CNS drugs in the mouse brain. Furthermore, the dynamic spatial changes of risperidone and its metabolite were visualized over a 24-h period. Also, the brain-to-plasma (B/P) ratio could be obtained according to MALDI MSI results, providing an alternative means to assess brain penetration in drug discovery.

© 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction

The total cost of drug development has more than doubled in the past decade with a high failure rate. Particularly, brain drug development has proven to be very difficult, for example, the failure rate of Alzheimer’s disease (AD) drug development was near 99.6%, which may hit investor confidence in innovation. For central nervous system (CNS) drug discovery, one of the fundamental principles is to cross the blood–brain barrier (BBB) and distribute at the target-site at sufficient concentration to execute its pharmacological effect. Several approaches have been developed for mapping brain regional distribution of small molecule drugs and assessing their brain penetration in CNS drug discovery. However, accurately mapping the spatial distribution of a drug or drug candidate in the brain is not always easy, maybe even worse for micro or trace amounts of drug metabolites. Liquid/gas chromatography–mass spectrometry (LC/GC–MS) and ligand binding assay (e.g., ELISA) are often used for quantitative analysis of target molecules in the biological sample, whereas the tissue homogenization is required resulting in the loss of spatial resolution. Whole-body autoradiography (WBA), positron emission tomography (PET), and fluorescence imaging offer the ability to visualize the tissue-specific distribution of drugs. However, these molecular imaging techniques rely on radiolabeled tracer or report probe, which is unable to distinguish parent drug from its metabolites because only the labeled compounds can be detected. Furthermore, the risk of label loss may occur in the metabolic process. Therefore, continuous development of imaging methods for precisely visualizing the distribution of small molecule drugs and their metabolites in brain tissues is critical to the research and development of CNS drugs, and non-CNS therapies, where brain penetration can cause unexpected CNS-mediated side effects.

Mass spectrometry imaging (MSI) appears to be a promising label-free imaging technique for interrogating the spatiotemporal distribution of endogenous compounds in various samples. The most frequently used MSI modality is matrix-assisted laser desorption/ionization (MALDI), which has been employed to map the tissue-specific distribution of small metabolites, lipids, peptides, and proteins. Currently, one of the most attractive applications of MALDI MSI is the visualization of tissue distribution of drug or drug candidates and their potential metabolites, providing essential spatial information for optimizing drug ADME properties. However, unlike LC/GC–MS, the traditional sample purification, concentration, and chromatographic separation are not available for MSI, in situ detection of small molecule drugs in tissue is greatly limited by ionization competition/suppression of highly abundant endogenous biomolecules and MALDI matrix. Furthermore, the amount of drug in a laser spot (~100 μm) on a 12 μm thick tissue is significantly low (~1 pg/spot). If the drug delivery were limited by BBB or nonspecifically and specifically bound with protein/lipid in tissue, the situation would be worse. This may be that the spatial distribution information of drug metabolites is often missed in the MSI of the parent drug.

To overcome these limitations, various strategies have been proposed for MALDI MSI of drugs to improve detection sensitivity and specificity. Discovery of novel organic matrices with high desorption/ionization (DI) of the analyte, synthesis of diverse nanomaterials, and nanostructured surfaces with low background noise and high DI efficiency have been intensively employed. Another option to minimize salts- and lipids-induced ion suppression is tissue pretreatment with a pH-controlled buffer solution or solid hydrogel prior to MALDI MSI. On-tissue derivatization via the introduction of the ionized group on target drug is also utilized to improve detection sensitivity in MALDI MSI. Although several MALDI MSI methods are successfully developed based on the physicochemical properties of individual drugs, the lack of universality largely hindered their broad application to the pharmaceutical industry.

It is well-known that the detection sensitivity of drug molecules could greatly increase by extracting them from complex samples to remove the ion suppression from endogenous components. However, the in situ extraction method for MALDI MSI is rarely reported and quite challenging. To achieve this goal, the laser-assisted chemical transfer (LACT) technique was introduced to extract the drug molecule in situ from the tissue without the damage of its spatial distribution. A rationally selected MALDI matrix able to absorb the laser radiation at operational wavelength was applied as the intermediate layer to drive in situ extraction and chemical transfer of the target drug molecules from tissue. LACT is a chemical transfer of exogenous components, enabling universal enhancement of MALDI detection sensitivity and visualization of the spatial distribution of CNS drug and its metabolite in brain tissue.

2. Results and discussion

The prototype LACT was designed inspired by laser-assisted transfer technique, such as infrared laser ablation sample transfer method and laser-capture microdissection technology. However, they are tissue transfer methods, an indiscriminate transfer, which cannot on-tissue separate target drug molecules from endogenous components. As shown in Fig. 1 A and Supporting Information Fig. S1, LACT employs a focused laser to illuminate the matrix-coated tissue placed on a donor slide in a transmission mode, and a thin film was transferred to another clean acceptor slide. The transfer is forced by strongly localized heat during laser illumination, resulting in a small volume of materials to be ablated from tissue and deposited onto the acceptor slide. LACT relies on the efficient absorption of laser energy in the tissue to obtain the optimal pattern and chemical transfer. Therefore, it is crucial to utilize a compound able to absorb laser radiation at an operational wavelength to assist chemical transfer, not tissue transfer. Ideally, if a MALDI matrix served both absorbing compounds for LACT and matrix for subsequent MALDI MSI, it could simplify the whole experiment and avoid introducing the new chemicals. Moreover, in LACT, an electric field-assisted sprayer was assembled and used to homogeneously deposit matrix solution. As proved in our previous work, compared with the conventional gas spray coating method, a micro-extraction could be induced by the electric field to facilitate the analyte moving from the tissue to the matrix layer. A desirable matrix should have a low ablation threshold and high absorption coefficient, which can effectively avoid excessive thermal effects and phase changes on tissue. Therefore, the mouse after dosing of venlafaxine was sacrificed and the brain section was sprayed with five often used matrices including DHAP, THAP, DAN, DHB, and CHCA to screen the suitable matrix for LACT. A diode laser source operated at the wavelength of 405 nm was assembled on the LACT device. The solid-state absorption spectra of five candidate matrices were acquired in the range of 350–600 nm. Among them, CHCA exhibits the highest absorption at 405 nm. As expected, the lowest energy threshold for chemical transfer was 4 mW when CHCA was applied. Although tissue sections coated with the
other four matrices could be transferred using a 405 nm laser (Fig. 1D), the venlafaxine could be detected with the highest sensitivity by using CHCA-LACT (Fig. 1C and D). Herein, the optimal matching between CHCA and 405 nm laser resulted in the requirement of minimum transfer energy and greatly minimized the risk of laser-induced thermal damage. In addition, the signal intensity of venlafaxine is inversely proportional to the thickness of the transferred film (Supporting Information Fig. S2). The thinnest film \( w \) mm could be achieved using 4 mW laser radiation with the highest signal intensity of venlafaxine (Fig. S2A). Increasing laser radiation above 16 mW, the signal intensity of venlafaxine largely decreases, and the spatial distribution pattern is hardly resolved. Additionally, to remove doubt regarding the analyte delocalization possibly caused by LACT, mouse brain dosed with a fluorescent dye was firstly imaged with fluorescence microscopy, and LACT treatment was subsequently performed for MALDI MSI at 200 \( \mu \)m raster step size to visualize the spatial distribution of fluorescein (m/z 333.11). As shown in Supporting Information Fig. S3A, the spatial distribution pattern of fluorescent dye obtained by using two techniques was consistent with each other, indicating that no significant compound delocalization occurred during the LACT process. Subsequently, the raster step size of 50 \( \mu \)m was applied to evaluate the possible compound delocalization. The fine distribution pattern of fluorescein was resolved, which was in a blood vessel with a diameter of \( \sim \) 50 \( \mu \)m, consistent with the fluorescence image (Fig. S3A). Furthermore, brain tissues from animals dosed with imipramine were subjected to LACT for MALDI MSI of its distribution in the cerebellum (Fig. S3B). Compared to the H&E-stained image, the ion image of imipramine acquired at 50 \( \mu \)m step size by MALDI MSI could resolve the stripe interval between cerebellar folium (\( \sim \) 100 \( \mu \)m) and the morphology of the granular layer and white matter. Additionally, a comparison of MALDI MSI results of venlafaxine measured in dosed mouse brain before and after LACT treatment using different matrices. DHAP, 2,6-dihydroxyacetophenone; THAP, 2,4,6-trihydroxy-acetophenone; DAN, 1,5-diaminonaphthalene; DHB, 2,5-dihydroxybenzoic acid; CHCA, \( \alpha \)-cyano-4-hydroxycinnamic acid.

Figure 1 Working principle of LACT and optimization of absorbing matrix compound for LACT and MALDI MSI. (A) Workflow for matrix deposition, laser illumination (405 nm), and chemical transfer. (B) Solid-state UV absorption spectra of different MALDI matrices coated on brain tissues. (C) The influence of transfer threshold energy on the signal intensities of venlafaxine. The transfer threshold energy was defined as the minimum real-time power of the laser (mW) necessary to achieve chemical transfer. Error bars indicate the standard deviations of 100 mass spectra acquired from ion images. (D) Comparison of MALDI MSI results of venlafaxine measured in dosed mouse brain before and after LACT treatment using different matrices. DHAP, 2,6-dihydroxyacetophenone; THAP, 2,4,6-trihydroxy-acetophenone; DAN, 1,5-diaminonaphthalene; DHB, 2,5-dihydroxybenzoic acid; CHCA, \( \alpha \)-cyano-4-hydroxycinnamic acid.
and lipids. Consequently, ionization competition and suppression from the tissue itself was greatly minimized, which was beneficial for the detection of exogenous compounds.

Moreover, the mixture solution of CNS drug and CHCA was homogenously spray-coated on the bare ITO slide and brain tissue to evaluate tissue extinction coefficient (TEC), which is used to account for ion suppression effects that occurred in MALDI MSI14. TEC is calculated by comparing the mean signal intensity of a standard obtained from the tissue and bare ITO slide. The strong signal intensity of venlafaxine was obtained from bare ITO slide and chemical film, however, the venlafaxine signal was markedly suppressed by untreated brain tissue (Fig. 2A). Similar results were observed for other 15 test CNS drugs (Supporting Information Fig. S7). As shown in Fig. 2B, the average TEC value for untreated tissues of 16 CNS drugs was 0.045, similar to previous reports14,31. However, the average TEC value for chemical films of 16 CNS drugs was 0.76, having a ~17-fold increase. TEC results suggested that the ion suppression is mainly derived from the tissue itself, and CHCA-LACT can provide a universal enhancement effect for selected CNS drugs.

Finally, the performance of the CHCA-LACT was evaluated for its sensitivity and linearity. As shown in Fig. 2C and Supporting Information Fig. S8, >1300-fold decrease in the limit of detection (LOD) of 16 CNS drugs was observed in the chemical films as compared to the untreated tissue. Therefore, the CHCA-LACT technique can significantly improve the MALDI MS detection sensitivity of various CNS drugs due to the global minimization of ionization competition/suppression effect from abundant components in tissue. To evaluate the linearity of the method, serial dilutions of venlafaxine and lamotrigine were manually spotted on the cortex of the blank brain tissue section, respectively, and LACT was subsequently performed. The calibration curve was generated for venlafaxine and lamotrigine by plotting average signal intensities of mass spectra in a defined region of interest (ROI) as a function of the concentration of standards spotted on the brain tissue section (Supporting Information Fig. S9). The MALDI MSI results exhibited ideal linearity ($R = 0.9953$ for venlafaxine and $R = 0.9925$ for lamotrigine) within the 100-fold concentration range.

The utility of CHCA-LACT was comprehensively demonstrated by MALDI MSI of 16 CNS drugs (including 6 antipsychotic drugs, 2 anesthetic drugs, 3 antidepressant drugs, 1 antiepileptic drug, 3 anti-Alzheimer drugs, and 1 antihypertensive drug) in brain tissues from mice receiving a single dose. Meanwhile, a comparison of CHCA-LACT with the other three methods (MALDI with CHCA, MALDI with DHB, and blank control) was performed to show the advantage of CHCA-LACT in the high detection sensitivity (Fig. 3). The blank tissue treated by CHCA-LACT was used to eliminate false positive. In situ tandem MS/MS was performed on dosed tissues treated by CHCA-LACT to validate the identity of the drug (Supporting Information Fig. S10 and Table S2). Undoubtedly, most CNS drugs were not detectable by conventional CHCA and DHB matrices, and no interference peak was observed in blank tissue. However, with the aid of CHCA-LACT, the brain regional distributions of 16 CNS drugs were successfully revealed in the horizontal sections of the mouse brains after i.p. dosing, showing the similarity and difference in spatial distribution. Relatively high levels of drugs were detected in the cerebral cortex followed by the hippocampus, thalamus, and striatum, generally in agreement with previous studies20,32. Distinct distribution patterns were visualized for specific drugs. For example, quite low levels of venlafaxine, fluoxetine, and lamotrigine were observed in the cerebellum as compared with the cortex and the rest of the brain regions, which were confirmed by previous HPLC and autoradiographic methods33–35. These results indicate that the

![Figure 2](image-url)  
Figure 2 Evaluation of tissue extinction coefficient (TEC) and limit of detection (LOD) of CHCA-LACT technique. (A) Ion images and representative MALDI mass spectra of venlafaxine acquired from bare ITO glass slide, untreated tissue, and chemical film. (B) Histogram of calculated TEC values for each CNS drug in untreated and CHCA-LACT treated brain tissue sections. (C) Representative MALDI mass spectra of venlafaxine at LOD level and LODs of 16 CNS drugs obtained from untreated and CHCA-LACT treated tissue sections.
CHCA-LACT technique provides a universal enhancement of signal intensities of CNS drugs enabling the accurate tissue-specific distributions of drugs in brain tissue. It is a very useful alternative means when the traditional MALDI MSI does not work.

The superior performance of CHCA-LACT was further demonstrated by interrogation of spatiotemporal changes of antipsychotic drug risperidone (RISP) and its metabolite in 24 h after single dosing. RISP and its one major pharmacologically active metabolite 9-hydroxy-risperidone (9-OH RISP) were readily detected by using MALDI MS with CHCA-LACT, and their spatiotemporal changes were unraveled for the first time (Fig. 4). After i.p. administration, the drug rapidly penetrated through the BBB into the brain, reaching maximum concentration \( T_{\text{max}} \) in ~15 min, and it was mainly observed in the frontal cortex, striatum, and hippocampus regions colocalized with the 5-HT and dopamine receptors. Subsequently, tissue concentration and distribution of RISP rapidly declined by 0.5 h from peak concentration, and a small amount of parent drug was only observed in the lateral ventricles after 2 h (Fig. 4A). However, 9-OH RISP reached \( T_{\text{max}} \) in 1 h and was spatially confined in the lateral ventricles as shown in Fig. 4B. As expected, the BBB permeability of hydroxylated metabolite is lower than its parent drug. Repeatability measurements of spatiotemporal changes of RISP and 9-OH RISP in dosed mice were conducted with three biological and technical replicates (Supporting Information Fig. S11). We further validated these results by using LC–MS/MS analysis on punched tissue homogenate (Fig. 4C and D). MALDI MS and LC–MS/MS results showed a good agreement with each other in terms of brain regional concentration–time profiles and signal intensity distributions (Fig. 4D and Supporting Information Fig. S12). This experiment illustrates that MALDI MSI with CHCA-LACT provides a powerful means to accurately address the problem of tissue distribution of the drug and its metabolites. Spatiotemporal information obtained here can improve our understanding of pharmacokinetics (PK), pharmacodynamics (PD), and potential transient toxicities of RISP and its metabolite in the brain.

The extended application was finally explored by assessment of drug brain penetration to illustrate the versatility of CHCA-LACT. Brain-to-plasma (B/P) ratio, vital data for successful CNS drug development, was applied to evaluate the extent of brain uptake of 10 known CNS drugs. Taking clozapine and tacrine for example, the ion signal of plasma heme B \((m/z 616.2) \) was utilized to segregate ion images of drugs into the brain parenchyma region and blood vessel individually (Supporting Information Figs. S13A and B). The B/P ratio was directly calculated by comparing average MS signal intensities of drugs in the brain parenchyma region to that of brain blood vessels (Fig. S13C). To validate our results, a correlation of the B/P ratio determined by MALDI MSI with CHCA-LACT and parallel artificial membrane permeability assay (PAMPA)-BBB data from literature was performed (Fig. S13D). As shown in Fig. S13E, the B/P ratio obtained by MALDI MSI correlated strongly with PAMPA-BBB data, with a correlation coefficient of \( R = 0.8917 \) and \( P = 0.0005 \) for 10 CNS drugs.
drugs, demonstrating that MALDI MSI with CHCA-LACT could be an attractive tool for assessing brain penetration of potential CNS drug candidate.

3. Conclusions

Our work provides an efficient sample preparation technique to overcome the limitations of the current MALDI MSI. The results proved that CHCA-LACT is a powerful and universally applicable technique, which enables unraveling the spatiotemporal distribution of drugs and their metabolite in brain tissue, as well as assessing drug penetration in the brain.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (Nos. 81973703 and 81803957), and the Natural Science Foundation of Jiangsu Province (No. BK20180567, China). The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.

Author contributions

Shuai Guo and Bin Li: conceptualisation, investigation, methodology, validation, and writing-original draft; Kening Li and Yanwen Chen: methodology and validation; Bin Li: conceptualisation, supervision, and writing-reviewing and editing.

Conflicts of interest

The authors declare no conflict of interest.

Appendix A. Supporting information

Supporting information to this article can be found online at https://doi.org/10.1016/j.apsb.2021.11.007.

References

1. Mullard A. New drugs cost US $2.6 billion to develop. Nat Rev Drug Discov 2014;13:877.
2. Cummings JL, Morstorf T, Zhong K. Alzheimer’s disease drug-development pipeline: few candidates, frequent failures. Alzheimer’s Res Ther 2014;6:1–7.
3. Morgan P, Brown DG, Lennard S, Anderton MJ, Barrett JC, Eriksson U, et al. Impact of a five-dimensional framework on R&D productivity at AstraZeneca. Nat Rev Drug Discov 2018;17:167.
4. Di L, Kerns EH, Carter GT. Strategies to assess blood–brain barrier penetration. Expet Opin Drug Discov 2008;3:677–87.
5. Wong ALA, Xiang X, Ong PS, Mitchell EQY, Syn N, Wee I, et al. A review on liquid chromatography-tandem mass spectrometry methods for rapid quantification of oncology drugs. Pharmaceutics 2018;10:221.
6. McEwen A, Henson C. Quantitative whole-body autoradiography: past, present and future. Bioanalysis 2015;7:557–68.
7. James ML, Gambhir SS. A molecular imaging primer: modalities, imaging agents, and applications. Physiol Rev 2012;92:897–965.
8. Chughtai K, Heeren RM. Mass spectrometric imaging for biomedical tissue analysis. Chem Rev 2010;110:3237–77.

Figure 4  Visualization of spatiotemporal changes of risperidone (RISP) and its metabolite 9-hydroxy-risperidone (9-OH RISP) in brain tissues after i.p. administration using MALDI MSI with CHCA-LACT. (A) Ion images of RISP and 9-OH RISP were acquired at different time points. (B) Chemical structures of RISP and 9-OH RISP, and optical image of the horizontal section of the mouse brain. (C) Comparison of relative intensities of RISP and 9-OH RISP at different brain regions determined by LC–MS/MS and MALDI MSI with CHCA-LACT, respectively. (D) Comparison of relative intensities of RISP and 9-OH RISP in the lateral ventricles at different time points determined by LC–MS/MS and MALDI MSI with CHCA-LACT, respectively. The results were expressed as the mean ± SD from three animals.
9. Li B, Dunham SJ, Dong Y, Yoon S, Zeng M, Sweedler JV. Analytical capabilities of mass spectrometry imaging and its potential applications in food science. *Trends Food Sci Technol* 2016;47:50–63.

10. Steuer AE, Poetzsch M, Kraemer T. MALDI-MS drug analysis in biological samples: opportunities and challenges. *Bioanalysis* 2016;8:1859–78.

11. Tang W, Gordon A, Wang F, Chen Y, Li B. Hyralazine as a versatile and universal matrix for high-molecular coverage and dual-polarity matrix-assisted laser desorption/ionization mass spectrometry imaging. *Anal Chem* 2021;93:9083–93.

12. Li B, Ge J, Liu W, Hu D, Li P. Unveiling spatial metabolome of *Paeonia suffruticoso* and *Paeonia lactiflora* roots using MALDI MS imaging. *New Phytol* 2021;231:892–902.

13. Tang W, Chen J, Zhou J, Ge J, Zhang Y, Li P, et al. Quantitative MALDI imaging of spatial distributions and dynamic changes of tetrandrine in multiple organs of rats. *Theranostics* 2019;9:932–44.

14. Taylor AJ, Dexter A, Bunch J. Exploring ion suppression in mass spectrometry imaging of a heterogeneous tissue. *Anal Chem* 2018;90:5637–45.

15. Vismeh R, Waldon DJ, Teffera Y, Zhao Z. Localization and quantification of drugs in animal tissues by use of desorption electrospray ionization mass spectrometry imaging. *Anal Chem* 2012;84:5439–45.

16. Wu Q, Chu JL, Rubakhin SS, Gillette MU, Sweedler JV. Dopamine-modified TiO2 monolith-assisted LDI MS imaging for simultaneous localization of small metabolites and lipids in mouse brain tissue with enhanced detection selectivity and sensitivity. *Chem Sci* 2017;8:3926–38.

17. Stopka SA, Rong C, Korte AR, Yadavilli S, Nazarian J, Razunguzwa TT, et al. Molecular imaging of biological samples on nanophotonic laser desorption ionization platforms. *Angew Chem* 2016;128:4558–62.

18. Shariatgorji M, Kallback P, Gustavsson L, Schintu N, Svenningsson P, Goodwin RJ, et al. Controlled-pH tissue cleanup protocol for signal enhancement of small molecule drugs analyzed by MALDI-MS imaging. *Anal Chem* 2012;84:4603–7.

19. Song X, Luo Z, Li X, Li T, Wang Z, Sun C, et al. In situ hydrogel conditioning of tissue samples to enhance the drug’s sensitivity in ambient mass spectrometry imaging. *Anal Chem* 2017;89:6318–23.

20. Chen Y, Tang W, Gordon A, Li B. Development of an integrated tissue pretreatment protocol for enhanced MALDI MS imaging of drug distribution in the brain. *J Am Soc Mass Spectrom* 2020;31:1086–73.

21. Shariatgorji R, Nilsson A, Fridjonsdottir E, Strittmatter N, Dannhorn A, Svenningsson P, et al. Spatial visualization of comprehensive brain neurotransmitter systems and neuroactive substances by selective in situ chemical derivatization mass spectrometry imaging. *Nat Protoc* 2021;16:3298–321.

22. Wu Q, Comi TJ, Li B, Rubakhin SS, Sweedler JV. On-tissue derivatization via electrospray deposition for matrix-assisted laser desorption/ionization mass spectrometry imaging of endogenous fatty acids in rat brain tissues. *Anal Chem* 2016;88:5988–95.

23. Serra P, Piqué A. Laser-induced forward transfer: fundamentals and applications. *Adv Mater Technol* 2019;4:1800099.

24. Park SG, Murray KK. Infrared laser ablation sample transfer for MALDI imaging. *Anal Chem* 2012;84:3240–5.

25. Espina V, Wolflkuhle JD, Calvert VS, VanMeter A, Zhou W, Coukos G, et al. Laser-capture microdissection. *Nat Protoc* 2006;1:586–603.

26. Guo S, Wang Y, Zhou D, Li Z. Electric field-assisted matrix coating method enhances the detection of small molecule metabolites for mass spectrometry imaging. *Anal Chem* 2015;87:5860–5.

27. Wang X, Han J, Yang J, Pan J, Borchers CH. Matrix coating assisted by an electric field (MCAEF) for enhanced tissue imaging by MALDI-MS. *Chem Sci* 2015;6:729–38.

28. Karnakis D, Lippert T, Ichinose N, Kawanishi S, Fukumura H. Laser induced molecular transfer using ablation of a triazeno-polymer. *Appl Surf Sci* 1998;127:781–6.

29. Boksamp MS, Soltwisch J. Charge distribution between different classes of glycerophospholipids in MALDI-MS imaging. *Anal Chem* 2020;92:5222–30.

30. Furey A, Moriarty M, Bane V, Kinsella B, Lehane M. Ion suppression; a critical review on causes, evaluation, prevention and applications. *Talanta* 2013;115:104–22.

31. Razagalski I, Kovacevic B, Hainz N, Meier C, Tschernig T, Volmer DA. Toward higher sensitivity in quantitative MALDI imaging mass spectrometry of CNS drugs using a nonpolar matrix. *Anal Chem* 2018;90:12592–600.

32. Vallianatou T, Shariatgorji M, Nilsson A, Fridjonsdottir E, Kallback P, Schintu N, et al. Molecular imaging identifies age-related attenuation of acetylcholine in retrosplenial cortex in response to acetylcholines- terase inhibition. *Neuropsychopharmacology* 2019;44:2091–8.

33. Murrell MD, Cruz DA, Javors MA, Thompson PM. Distribution of venlafaxine, O-desmethylvenlafaxine, and O-desmethylvenlafaxine to venlafaxine ratio in postmortem human brain tissue. *J Forensic Sci* 2014;59:683–9.

34. Mukherjee J, Das MK, Yang ZY, Lew R. Evaluation of the binding of the radiolabeled antidepressant drug, 18F-fluoxetine in rat brain: an in vitro and in vivo study. *Nucl Med Biol* 1998;25:605–10.

35. Serrallehro A, Alves G, Fortuna A, Falcão A. Direct nose-to-brain delivery of lamotrigine following intranasal administration to mice. *Int J Pharm* 2015;490:39–46.

36. van Beijsterveldt LE, Geerts RJ, Leysen JE, Megens AA, Van den Eynde HM, Meuldersman WE, et al. Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. *Psychopharmacology (Berl)* 1994;114:53–62.

37. Di L, Kerns EH, Fan K, McConnell OJ, Carter GT. High throughput artificial membrane permeability assay for blood–brain barrier. *Eur J Med Chem* 2003;38:223–32.

38. Di L, Kerns EH, Bezar IF, Petusky SL, Huang Y. Comparison of blood–brain barrier permeability assays: in situ brain perfusion, MDR1-MDCKII and PAMPA-BBB. *J Pharm Sci* 2009;98:1980–91.